Patents by Inventor Isabel MUHLEN-BARTMER

Isabel MUHLEN-BARTMER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220202711
    Abstract: The application relates to an aqueous pharmaceutical formulation for use in the treatment of Type I or Type II Diabetes Mellitus, wherein the treatment reduces the risk of nocturnal hypoglycemia, said formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine, with the proviso that the concentration of said formulation is not 684 U/mL of insulin glargine.
    Type: Application
    Filed: December 2, 2021
    Publication date: June 30, 2022
    Inventors: Isabel MUHLEN-BARTMER, Monika ZIEMEN
  • Patent number: 11191722
    Abstract: The application relates to an aqueous pharmaceutical formulation for use in the treatment of Type I or Type II Diabetes Mellitus, wherein the treatment reduces the risk of nocturnal hypoglycemia, said formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine, with the proviso that the concentration of said formulation is not 684 U/mL of insulin glargine.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: December 7, 2021
    Inventors: Isabel Muhlen-Bartmer, Monika Ziemen
  • Publication number: 20200170945
    Abstract: The application relates to an aqueous pharmaceutical formulation for use in the treatment of Type I or Type II Diabetes Mellitus, wherein the treatment reduces the risk of nocturnal hypoglycemia, said formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine, with the proviso that the concentration of said formulation is not 684 U/mL of insulin glargine.
    Type: Application
    Filed: December 2, 2019
    Publication date: June 4, 2020
    Inventors: Isabel MUHLEN-BARTMER, Monika ZIEMEN
  • Publication number: 20190060233
    Abstract: The application relates to an aqueous pharmaceutical formulation for use in the treatment of Type I or Type II Diabetes Mellitus, wherein the treatment reduces the risk of nocturnal hypoglycemia, said formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine, with the proviso that the concentration of said formulation is not 684 U/mL of insulin glargine.
    Type: Application
    Filed: August 30, 2018
    Publication date: February 28, 2019
    Inventors: Isabel MUHLEN-BARTMER, Monika ZIEMEN
  • Patent number: 10092513
    Abstract: The application relates to an aqueous pharmaceutical formulation for use in the treatment of Type I or Type II Diabetes Mellitus, wherein the treatment reduces the risk of nocturnal hypoglycemia, said formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine, with the proviso that the concentration of said formulation is not 684 U/mL of insulin glargine.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: October 9, 2018
    Assignee: SANOFI
    Inventors: Isabel Muhlen-Bartmer, Monika Ziemen
  • Publication number: 20160030339
    Abstract: The application relates to an aqueous pharmaceutical formulation for use in the treatment of Type I or Type II Diabetes Mellitus, wherein the treatment reduces the risk of nocturnal hypoglycemia, said formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine, with the proviso that the concentration of said formulation is not 684 U/mL of insulin glargine.
    Type: Application
    Filed: April 1, 2014
    Publication date: February 4, 2016
    Inventors: Isabel MUHLEN-BARTMER, Monika ZIEMEN